Table 1 Patient characteristics and intraoperative data
Remifentanil (n = 38) | Dexmedetomidine (n = 38) | P value | |
|---|---|---|---|
Age, year | 55.1 (10.0) | 50.9 (10.1) | 0.076 |
Gender, male | 17 (44.7%) | 16 (42.1%) | 0.817 |
Weight, kg | 57.3 (7.9) | 61.8 (11.0) | 0.041 |
Height, Cm | 165.6 (8.0) | 163.3 (10.0) | 0.273 |
Body mass index, kg/m2 | 21.0 (3.3) | 23.0 (2.3) | 0.003 |
ASA PS classification, I/II | 21/17 | 15/23 | 0.168 |
Diagnosis | 0.073 | ||
Gastric ca. | 2 (5.3%) | 1 (2.6%) | |
Breast ca. | 9 (23.7%) | 4 (10.5%) | |
Colon ca. | 8 (21.1%) | 4 (10.5%) | |
Ovary, cervix ca. | 3 (7.9%) | 1 (2.6%) | |
Pancreas ca. | 12 (31.6%) | 6 (15.8%) | |
Thyroid ca. | 0 | 2 (5.3%) | |
Rectal ca. | 4 (10.5%) | 18 (47.4%) | |
Jejunal, intrahepatic bile duct ca. | 0 | 2 (5.3%) | |
Duration | |||
Anesthesia duration, min | 59.7 (10.4) | 52.8 (8.1) | 0.002 |
Surgery duration, min | 42.6 (13.2) | 35.0 (8.0) | 0.004 |
PACU staying, min | 34.3 (1.9) | 33.9 (2.0) | 0.411 |
Drug consumption | |||
Propofol, mg | 252.6 (67.7) | 174.9 (44.0) | 0.010 |
Study drug, mg | 0.2 (0.1) | 33.0 (23.5) | - |
Midazolam, mg | 1.6 (0.6) | 1.6 (0.8) | 0.942 |
Additional analgesics | 0 | 0 | - |